Nicox SA ALCOX

Press Release Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026September 16, 2026 – release at 7:30 amSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that key scientific data on NCX 470 will be presented at the upcoming American Academy of Optometry (AAOpt) Annual Meeting 2026 (September 30 – October 3, 2026, Anaheim, CA, U.S.). Nicox will also be participating in several key ophthalmology,

Press Release Nicox Announces Extension of Cash Runway Cash position, of €8.4 million1 as of 31 August 2026, sufficient to fund existing operations beyond Q1 2028NCX 470 U.S. NDA approval milestone would fund operations into 2029, while subsequent royalties could extend the cash runway substantially further Discussions on future strategic opportunities continuing September 2, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an internatio

Press Release Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma FDA sets Prescription Drug User Fee Act (PDUFA) review response date by 30 April 2027Two NDAs filed in major markets, with commercial partners in place for expected launches from H2 2027 onwardsMilestone payment due on U.S. NDA approval plus royalties on salesNCX 470 Phase 3 program ongoing in Japan in support of approvalQ&A available on Nicox’s website August 27, 2026 – release at 7:30 am CETSophia Antipolis, FranceNico

Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment NCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) by exclusive licensee Kowa Company, Ltd. (Kowa) for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension€3 million milestone payment due to Nicox, with a further milestone payment due upon approvalSubmission based on posit

Press Release Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company Shareholder loan agreement for up to €6.0 million over 3 yearsCompany is currently well-financed, and this shareholder operation provides additional flexibility to support its strategic activitiesNo obligation for Nicox to draw down any amount and maximum potential dilution is cappedIf drawn down, loans are repayable in new shares or in cash. In the event of a drawdown of the ma

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil", 000520.KS), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in Vietnam. Samil, established in 1947, is one of the most prominent Korean manufacturers

Press Release Reminder: Nicox June 2024 Warrants will expire June 19, 2026June 8, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today reminds holders of the warrants issued in June 2024 as part of the Company’s equity offering with preemptive rights that these warrants will expire on Friday, June 19, 2026, close of market day, after which date they will have no value. The last possible date for

Press Release Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representativeJune 3, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, reminds its shareholders that the Ordinary and Extraordinary General Meeting will be held on Wednesday, June 24, 2026 at 2:30 p.m., at the Company’s headquarters located at Sundesk Sophia Antipolis, r

Press Release Nicox Provides Full Year 2025 Financial Results and Corporate Update Revenue of €16.8 million (€7.9 million in 2024) Net loss significantly reduced to €2.4 million (€22.4 million in 2024)NCX 470 U.S. New Drug Application (NDA) submission on track for summer 2026, with associated milestone paymentRegulatory milestones anticipated to extend cash runway beyond 2027 April 30, 2026 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an